Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524—A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation
Douglas M. Dahl, Theodore Karrison, M. Dror Michaelson, Huong Pham, Chin‐Lee Wu, Gregory P. Swanson, William U. Shipley, Jacqueline Vuky, R. Jeffrey Lee, Anthony L. Zietman, Luís Souhami, Brian K. Chang, Richard L. Deming, John Ellerton, Howard M. Sandler, Joseph P. Rodgers, Felix Y. Feng, Jason A. Efstathiou
Topics & Concepts
MedicineCystectomyInternal medicineOncologyClinical endpointRadiation therapyTrastuzumabBladder cancerToxicityPaclitaxelChemotherapyUrologyRandomized controlled trialCancerBreast cancerBladder and Urothelial Cancer TreatmentsEsophageal Cancer Research and TreatmentUrinary and Genital Oncology Studies